Prevalence and clinical features of psoriatic arthritis in psoriasis patients in Spain. Limitations of PASE as a screening tool

详细信息    查看全文

• 作者：Jose Luis L贸pez Estebar谩nz ; Pedro Zarco-Montejo…
• 关键词：assessment ; dermatologist ; diagnosis ; prevalence ; psoriasis ; psoriatic arthritis ; rheumatologist
• 刊名：European Journal of Dermatology
• 出版年：2015
• 出版时间：January 2015
• 年：2015
• 卷：25
• 期：1
• 页码：57-63
• 全文大小：
• 参考文献：1.Gladman DD. Psoriatic arthritis from Wright鈥檚 era until today. J Rheumatol 2009; 36(Suppl 83): 4鈥?.
  2.Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis: a literature review from a global health systems perspective. P T. 2010; 35: 680鈥?.PubMed Central PubMed
  3.Boehncke WH, Menter A. Burden of disease: psoriasis and psoriatric arthritis. Am J Clin Dermatol 2013; 14: 377鈥?8.CrossRef PubMed
  4.Kane D, Pathare S. Early psoriatic arthritis. Rheum Dis Clin North Am 2005; 31: 641鈥?7.CrossRef PubMed
  5.Lindqvist UR, Alenius GM, Husmark T, Theander E, Holmstr枚m G, Larsson PT, Psoriatic Arthritis Group of the Society for Rheumatology PT. The Swedish early psoriatic arthritis register 鈥?2-year followup: a comparison with early rheumatoid arthritis. J Rheumatol 2008; 35: 668鈥?3.PubMed
  6.McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford) 2003; 42: 778鈥?3.CrossRef
  7.National Psoriasis Foundation. 2011 Survey Panel Snapshot. Available at: www.psoriasis.org/document.doc?id=1782. Accessed May 2, 2013.
  8.Chang CA, Gottlieb AB, Lizzul PF. Management of psoriatic arthritis from the view of the dermatologist. Nat Rev Rheumatol 2011; 7: 588鈥?8.PubMed
  9.Qureshi AA, Husni ME, Mody E. Psoriatic arthritis and psoriasis: need for a multidisciplinary approach. Semin Cutan Med Surg 2005; 24: 46鈥?1.CrossRef PubMed
  10.Fern谩ndez Sueiro JL, Lema Gontad JM. Prognostic factors in psoriatic arthritis. [Article in Spanish]. Reumatol Clin 2012; 8(Suppl 1): S7鈥?.CrossRef PubMed
  11.Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2011; 69: 48鈥?3.CrossRef
  12.Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken) 2010; 62: 965鈥?.CrossRef
  13.Garc铆a-Diez A, Foraster CF, Sebasti谩n FV, Tudela LL, Llach XB, Fern谩ndez GS. What characterizes the severity of psoriasis? Results from an epidemiological study of over 3,300 patients in the Iberian region. Dermatology 2008; 216: 137鈥?1.CrossRef PubMed
  14.Husni ME, Meyer KH, Cohen DS, Mody E, Qureshi AA. The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol 2007; 57: 581鈥?.CrossRef PubMed
  15.Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4: 353鈥?5.CrossRef PubMed
  16.Moll JMH, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3: 55鈥?8.CrossRef PubMed
  17.Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665鈥?3.CrossRef PubMed
  18.Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2289鈥?1.
  19.Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 2281鈥?.PubMed
  20.Altobelli E, Maccarone M, Petrocelli R, et al. Analysis of health care and actual needs of patients with psoriasis: a survey on the Italian population. BMC Public Health 2007; 7: 59.CrossRef PubMed Central PubMed
  21.Reich K, Kr眉ger K, M枚ssner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 2009; 160: 1040鈥?.CrossRef PubMed
  22.Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64(Suppl 2): ii14鈥?.
  23.Dominguez PL, Husni ME, Holt EW, Tyler S, Qureshi AA. Validity, reliability, and sensitivity-to-change properties of the psoriatic arthritis screening and evaluation questionnaire. Arch Dermatol Res 2009; 301: 573鈥?.CrossRef PubMed Central PubMed
  24.Husni ME, Qureshi AA, Koenig AS, Pedersen R, Robertson D. Utility of the PASE questionnaire, psoriatic arthritis (PsA) prevalence and PsA improvement with anti-TNF therapy: results from the PRISTINE trial. J Dermatolog Treat 2014; 25: 90鈥?.CrossRef PubMed
  25.Walsh JA, Callis Duffin K, Krueger GG, Clegg DO. Limitations in screening instruments for psoriatic arthritis: a comparison of instruments in patients with psoriasis. J Rheumatol 2013; 40: 287鈥?3.CrossRef PubMed
  26.Haroon M, Kirby B, Fitzgerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis 2013; 72: 736鈥?0.CrossRef PubMed
  27.Coates LC, Aslam T, Al Balushi F, et al. Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study). Br J Dermatol 2013; 168: 802鈥?.CrossRef PubMed
  28.Ibrahim GH, Buch MH, Lawson C, Waxman R, Helliwell PS. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin Exp Rheumatol 2009; 27: 469鈥?4.PubMed
  29.Gladman DD, Schenta CT, Brian DMT, et al. Development and initial validation of a screening questionnaire for psoriatic arthritis: The Toronto Psoriatic Arthritis Screen (ToPAS). Ann Rheum Dis 2009; 68: 497鈥?01.CrossRef PubMed
  30.Coates LC, Conaghan PG, Emery P, et al. Sensitivity and specificity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum 2012; 64: 3150鈥?.CrossRef PubMed
  31.Gladman DD. Axial disease in psoriatric arthritis. Curr Rheumatol Rep 2007; 9: 455鈥?0.CrossRef PubMed
  32.Gladman DD. Inflammatory spinal disease in psoriatric arthritis: A report from the GRAPPA 2010 Annual Meeting. J Rheumatol 2012; 39: 418鈥?0.CrossRef PubMed
  33.Chang CA, Gottlieb AB, Lizzul PF. Management of psoriatic arthritis from the view of the dermatologist. Nat Rev Rheumatol 2011; 7: 588鈥?8.PubMed
  
• 作者单位：Jose Luis L贸pez Estebar谩nz (1)
  Pedro Zarco-Montejo (2)
  M. Luz Samaniego (3)
  Carmen Garc铆a-Calvo (4)
  On behalf of the PREVAL Study Group
  
  1. Department of Dermatology, Fundaci贸n Hospital Alcorc贸n, Madrid, Spain
  2. Department of Rheumatology, Fundaci贸n Hospital Alcorc贸n, Madrid, Spain
  3. Statistical Department, Trial Form Support, Madrid, Spain
  4. Medical Department, Pfizer Spain, Avenida de Europa 20B, Parque Empresarial La Moraleja, Alcobendas, Madrid, Spain
  
• 刊物类别：Dermatology;
• 刊物主题：Dermatology;
• 出版者：John Libbey Eurotext
• ISSN：1952-4013

文摘

Background Diagnosing and initiating treatment of psoriatric arthritis (PsA) as early as possible is essential to prevent irreversible joint destruction and poor clinical outcomes. Dermatologists are uniquely placed to identify early symptoms of PsA in psoriasis patients but levels of under- and late-diagnosis remain high.